Carlsmed (CARL) Net Income towards Common Stockholders (2024 - 2026)

Carlsmed's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$8.7 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 37.75% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.6 million (down 26.78% YoY) and the FY2025 annual result came in at -$30.2 million, down 21.61% from the prior year.
• Net Income towards Common Stockholders was -$8.7 million for Q1 2026 at Carlsmed, down from -$8.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$4.7 million in Q4 2024 and bottomed at -$8.7 million in Q1 2026.
• A 3-year average of -$7.3 million and a median of -$7.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 1.44% in 2025, while the deepest fall reached 82.48% in 2025.
• Carlsmed's Net Income towards Common Stockholders stood at -$4.7 million in 2024, then tumbled by 82.48% to -$8.6 million in 2025, then fell by 0.96% to -$8.7 million in 2026.
• Business Quant data shows CARL's Net Income towards Common Stockholders at -$8.7 million in Q1 2026, -$8.6 million in Q4 2025, and -$8.5 million in Q3 2025.